Sagard overview:
Sagard is a multi-strategy alternative asset management firm with more than US$25bn under management, 150 portfolio companies, and 300 professionals.
We invest in venture capital, private equity, private credit, real estate, and royalties. We deliver flexible capital, an entrepreneurial culture, and a global network of investors, commercial partners, advisors, and value creation experts. Our dynamic and supportive ecosystem gives our partners the advantage they need to learn, grow and win at every stage.
Sagard also engages in private wealth management through its ecosystem partner Grayhawk.
Our dedicated value creation team provides portfolio companies with hands-on expert advice in go-to-market, tech & cyber, business acceleration and M&A, and partnerships to accelerate their path to success. Our Partnerships team also facilitates long-term commercial collaboration opportunities.
The firm has offices in Canada, the United States, Europe and the Middle East.
More athttps://www.sagard.com/.
Position overview:
Supporting the Sagard Healthcare Partners team at Sagard Holdings, the selected candidate will work directly with the Analysts and Associates and be actively involved in the due diligence, financial modeling, and execution of healthcare royalty and credit investments. This position provides a unique and exciting opportunity to invest in the biopharmaceutical industry and to contribute to the success of a fast-growing alternative asset manager. We are a dynamic and entrepreneurial team focused on building a business for the long run.
Your Responsibilities:
Experience & Qualifications:
Our ideal candidate:
Sagard is an equal opportunity employer, which values diversity in the workplace. We are therefore happy to accommodate any individual. If you require accommodation in order to participate in the hiring process, please contact the People & Culture team to make your needs known in advance.
We welcome all applications and wish to thank all candidates for their interest in applying for this position. However, only individuals selected for interviews will be contacted.
#J-18808-Ljbffr